BioTuesdays

Category - Markets

Markets

Cantor starts Health Catalyst at OW; PT $16

Cantor Fitzgerald launched coverage of Health Catalyst (NASDAQ:HCAT) with an “overweight” rating and price target of $16, representing a 2024 enterprise value/revenue multiple of 2.3 times. The stock closed at $14.03 on...

August 1, 2023
Markets

Cantor starts Belite Bio at OW; PT $43

Cantor Fitzgerald launched coverage of Belite Bio (NASDAQ:BITR) with an “overweight” rating and a 12-month price target of $43. Belite listed its ADSs on NASDAQ in April 2022; they closed at $20.55 on July 27. Belite...

July 28, 2023
Aeglea-Bio-Logo
Markets

Stifel starts Aeglea Bio at buy; PT 90 cents

Stifel initiated coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and price target of 90 cents. The stock closed at 59 cents on July 24. Aeglea is a biotechnology company that is now focused on the...

July 25, 2023
Markets

Cantor starts LifeMD at OW; PT $7

Cantor Fitzgerald initiated coverage of LifeMD (NASDAQ:LFMD) with an “overweight” rating and price target of $7. The stock closed at $3.53 on July 20. “We see LifeMD as an undervalued, below-the-radar growth story in...

July 21, 2023
Orthofix-Logo
Markets

BTIG reinitiates Orthofix Medical at buy; PT $27

BTIG reinitiated its coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and $27 price target. The stock closed at $20.65 on July 18. BTIG previously covered the legacy Orthofix from 2017-to-2021 and the...

July 19, 2023
Markets

Cantor starts AVITA Medical at OW; PT $23

Cantor Fitzgerald launched coverage of AVITA Medical (NASDAQ:RCEL) with an “overweight” rating and $23 target price. The stock closed at $15.71 on June 26. Avita is a regenerative medicine company commercializing its...

June 27, 2023
Markets

restor3d to acquire Conformis for $2.27 a share

Closely-held restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of Conformis (NASDAQ:CFMS) for $2.27 a share, which represents an approximate 96% premium to the closing...

June 23, 2023
Fusion
Markets

Raymond James starts Fusion Pharma at OP; PT $13

Raymond James initiated coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with an “outperform” rating and $13 price target. The stock closed at $4.37 on June 22. Fusion is a precision oncology company that has built a...

June 23, 2023